Table 1.
Distribution of received and SARS-CoV-2 laboratory-confirmed specimens per origin, age group, and sex in each pandemic wave.
| 1st wave (weeks 11–26) | 2nd wave (weeks 27–52) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total/positive (%) | 55,625 / 8755 (15.7%) | 366,511 / 38,142 (10.4%) | ||||||||||||||
| Origin | HUVH | Primary care | HUVH | Primary care | ||||||||||||
| Tested | Positive | Tested | Positive | Tested | Positive | Tested | Positive | |||||||||
| Total (%)/positive (%)* | 36,734 | 66% | 6972 | 19% | 18,891 | 44% | 1783 | 9% | 91,298 | 25% | 4996 | 5% | 27,5213 | 75% | 33,146 | 12% |
| Median age (IQR) | 55 (38–75) | 58 (42–79) | 49 (35–66) | 60 (44–82) | 48 (30–67) | 51 (33–72) | 32 (16–51) | 38 (22–55) | ||||||||
| Age group (years)** | Total | % | + | % | Total | % | + | % | Total | % | + | % | Total | % | + | % |
| <5 | 1133 | 3% | 52 | 5% | 430 | 2% | 6 | 1% | 4627 | 5% | 109 | 2% | 15,130 | 6% | 943 | 6% |
| 5–14 | 841 | 2% | 23 | 3% | 467 | 3% | 13 | 3% | 3819 | 4% | 96 | 3% | 44,087 | 16% | 3007 | 7% |
| 15–40 | 8276 | 23% | 1430 | 17% | 5723 | 30% | 395 | 7% | 29030 | 32% | 1758 | 6% | 111,117 | 40% | 15,049 | 14% |
| 41–64 | 12,244 | 33% | 2441 | 20% | 7368 | 39% | 614 | 8% | 29305 | 32% | 1591 | 5% | 72,120 | 26% | 10,170 | 14% |
| > 64 | 14,240 | 39% | 3026 | 21% | 4903 | 26% | 755 | 15% | 24517 | 27% | 1442 | 6% | 32,759 | 12% | 3977 | 12% |
| % female | 21,167 | 58% | 3985 | 19% | 11,965 | 63% | 1166 | 10% | 52074 | 57% | 2672 | 5% | 157,399 | 57% | 17,957 | 11% |
| % male | 15,351 | 42% | 2964 | 19% | 6924 | 37% | 616 | 9% | 39094 | 43% | 2321 | 6% | 117,769 | 43% | 15,178 | 13% |
| 3rd wave (weeks 53–12) | 4th wave (weeks 13–24) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 146,504 / 11,866 (8.1%) | 87,120 / 6853 (7.9%) | ||||||||||||||
| HUVH | Primary care | HUVH | Primary care | ||||||||||||
| Tested | Positive | Tested | Positive | Tested | Positive | Tested | Positive | ||||||||
| 45,927 | 31% | 2475 | 5% | 100,577 | 69% | 9391 | 9% | 33,150 | 38% | 860 | 3% | 53,970 | 62% | 5993 | 11% |
| 51 (32–70) | 58 (35–76) | 35 (16–53) | 38 (20–55) | 55 (32–72) | 60 (39–76) | 27 (15–45) | 33 (17–49) | ||||||||
| Total | % | + | % | Total | % | + | % | Total | % | + | % | Total | % | + | % |
| 1804 | 4% | 32 | 2% | 1882 | 2% | 295 | 16% | 2396 | 7% | 21 | 1% | 1503 | 3% | 272 | 18% |
| 4597 | 10% | 187 | 4% | 7285 | 7% | 845 | 12% | 11,715 | 35% | 369 | 3% | 6053 | 11% | 600 | 10% |
| 13,690 | 30% | 680 | 5% | 36,630 | 36% | 3499 | 10% | 7826 | 24% | 194 | 2% | 24,359 | 45% | 2475 | 10% |
| 14,360 | 31% | 729 | 5% | 39,902 | 40% | 3286 | 8% | 9778 | 30% | 254 | 3% | 17,328 | 32% | 1838 | 11% |
| 11,476 | 25% | 847 | 7% | 14,878 | 15% | 1466 | 10% | 1435 | 4% | 22 | 2% | 4727 | 9% | 808 | 17% |
| 26,384 | 57% | 1384 | 5% | 68,246 | 68% | 5502 | 7% | 17,544 | 53% | 458 | 3% | 30,727 | 57% | 3135 | 10% |
| 19,537 | 43% | 1091 | 6% | 32,307 | 32% | 3888 | 9% | 15,603 | 47% | 402 | 3% | 23,242 | 43% | 2858 | 12% |
*Percentages of total samples received and positive by pandemic wave were calculated relative to the total specimens shown in the second row; percentages from positive samples were calculated depending on the total specimens received per pandemic wave and site.
**Percentages of total samples received by age group were calculated relative to the total specimens by clinical setting and pandemic wave shown in the fourth row; percentages from positive samples were performed horizontally, depending on the total specimens received per age group